Condition: Advanced Cervical Cancer · Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
This description comes directly from the study's public registry record.
Xiaoxu Zhang · +86-0518-82342973 · xiaoxu.zhang@hengrui.com
Zhaoyu Zhong · +86-0518-82342973 · zhaoyu.zhong.zz8@hengrui.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07168200